Feng Gu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Feng Gu has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- David A. Prince
Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA
1 shared publication Frank M. Longo
Department of Neurology & Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305-5122
1 shared publicationIsabel Parada
Department of Neurology & Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305-5122
1 shared publication- Tao Yang
Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA 94305, USA
1 shared publication
Latest Publications
- Open Access
- 14 February 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (7)
Chronic partial TrkB activation reduces seizures and mortality in a mouse model of Dravet syndrome
Significance: Dravet syndrome (DS) is a severe childhood epileptic encephalopathy characterized by intractable seizures and comorbidities, including a high rate of premature mortality. DS is mainly caused by loss-of-function mutations of the Scn1a gene encoding sodium channel Na v 1.1 that is predominantly expressed in inhibitory parvalbumin-containing (PV) interneurons. Decreased Na v 1.1 impairs PV cell function, causing DS phenotypes. Effective pharmacological therapy targeting defective PV interneurons is currently not available. This study demonstrated that early treatment with a partial TrkB receptor agonist, LM22A-4, increased Na v 1.1 expression, improved PV interneuron function, and reduced seizure occurrence and mortality rate in DS mice, suggesting a potential therapy for DS.
- 14 February 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (7)
Open AccessChronic partial TrkB activation reduces seizures and mortality in a mouse model of Dravet syndrome
Significance: Dravet syndrome (DS) is a severe childhood epileptic encephalopathy characterized by intractable seizures and comorbidities, including a high rate of premature mortality. DS is mainly caused by loss-of-function mutations of the Scn1a gene encoding sodium channel Na v 1.1 that is predominantly expressed in inhibitory parvalbumin-containing (PV) interneurons. Decreased Na v 1.1 impairs PV cell function, causing DS phenotypes. Effective pharmacological therapy targeting defective PV interneurons is currently not available. This study demonstrated that early treatment with a partial TrkB receptor agonist, LM22A-4, increased Na v 1.1 expression, improved PV interneuron function, and reduced seizure occurrence and mortality rate in DS mice, suggesting a potential therapy for DS.